Novelion Therapeutics (NASDAQ: NVLN) and Repros Therapeutics (NASDAQ:RPRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership.

Institutional & Insider Ownership

75.6% of Novelion Therapeutics shares are held by institutional investors. Comparatively, 13.6% of Repros Therapeutics shares are held by institutional investors. 14.1% of Novelion Therapeutics shares are held by insiders. Comparatively, 2.5% of Repros Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Novelion Therapeutics and Repros Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Novelion Therapeutics -108.10% -57.36% -11.88%
Repros Therapeutics -4,242.73% -894.22% -230.71%

Volatility and Risk

Novelion Therapeutics has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Repros Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.

Earnings & Valuation

This table compares Novelion Therapeutics and Repros Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Novelion Therapeutics $13.57 million 5.03 -$52.87 million ($6.99) -0.52
Repros Therapeutics $50,000.00 340.22 -$17.27 million ($0.50) -0.86

Repros Therapeutics has lower revenue, but higher earnings than Novelion Therapeutics. Repros Therapeutics is trading at a lower price-to-earnings ratio than Novelion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Novelion Therapeutics and Repros Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novelion Therapeutics 0 2 0 0 2.00
Repros Therapeutics 0 1 0 0 2.00

Novelion Therapeutics currently has a consensus target price of $8.00, indicating a potential upside of 118.58%. Repros Therapeutics has a consensus target price of $0.39, indicating a potential downside of 9.30%. Given Novelion Therapeutics’ higher probable upside, equities analysts plainly believe Novelion Therapeutics is more favorable than Repros Therapeutics.

Summary

Novelion Therapeutics beats Repros Therapeutics on 8 of the 11 factors compared between the two stocks.

About Novelion Therapeutics

Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company’s portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

About Repros Therapeutics

Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company’s Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.

Receive News & Ratings for Novelion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novelion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.